Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.45 |
| ▸ | PADI4 | Q9UM07 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GCGR | P47871 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879242 | 1.00 | KDM1A (0.45) | KDM1APADI4HPGDGCGRCNR1 | |
| SCHEMBL2881431 | 0.94 | PADI4 (0.42) | KDM1APADI4GCGRCNR1HRH3 | |
| SCHEMBL2881363 | 0.94 | PADI4 (0.42) | KDM1APADI4GCGRCNR1HRH3 | |
| SCHEMBL2879601 | 0.86 | HRH3 (0.54) | HPGDPKMSMN1; SMN2HRH3 | |
| SCHEMBL2885504 | 0.86 | HRH3 (0.54) | HPGDPKMSMN1; SMN2HRH3 | |
| SCHEMBL2887544 | 0.86 | HRH3 (0.54) | HPGDPKMSMN1; SMN2HRH3 | |
| SCHEMBL5483868 | 0.84 | HPGD (0.48) | HPGDCNR1PKMSMN1; SMN2HRH3 | |
| SCHEMBL2878841 | 0.80 | HRH3 (0.57) | HRH3MEN1KMT2A | |
| SCHEMBL2886402 | 0.80 | HRH3 (0.57) | HRH3MEN1KMT2A | |
| SCHEMBL14275540 | 0.73 | HSD17B10 (0.61) | HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | claimed |
| EP-1994022-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | claimed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | claimed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1994022-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | KDM1A 540/4885PADI4 497/4885HPGD 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.